Awakn Life Sciences Past Earnings Performance
Past criteria checks 0/6
Awakn Life Sciences has been growing earnings at an average annual rate of 37%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 47.5% per year.
Key information
37.0%
Earnings growth rate
47.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -47.5% |
| Return on equity | n/a |
| Net Margin | -3,479.8% |
| Last Earnings Update | 31 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Awakn Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jul 24 | 0 | -3 | 2 | 1 |
| 30 Apr 24 | 0 | -4 | 3 | 1 |
| 31 Jan 24 | 0 | -4 | 3 | 1 |
| 31 Oct 23 | 0 | -3 | 4 | 1 |
| 31 Jul 23 | 0 | -3 | 4 | 1 |
| 30 Apr 23 | 0 | -3 | 3 | 1 |
| 31 Jan 23 | 0 | -5 | 4 | 1 |
| 31 Oct 22 | 0 | -8 | 5 | 3 |
| 31 Jul 22 | 0 | -10 | 6 | 3 |
| 30 Apr 22 | 0 | -18 | 7 | 4 |
| 31 Jan 22 | 0 | -16 | 6 | 3 |
| 31 Oct 21 | 0 | -13 | 4 | 2 |
Quality Earnings: 954 is currently unprofitable.
Growing Profit Margin: 954 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 954 is unprofitable, but has reduced losses over the past 5 years at a rate of 37% per year.
Accelerating Growth: Unable to compare 954's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 954 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 954's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.